[HTML][HTML] SARS-CoV-2 and the host cell: a tale of interactions

M Pizzato, C Baraldi, G Boscato Sopetto… - Frontiers in …, 2022 - frontiersin.org
The ability of a virus to spread between individuals, its replication capacity and the clinical
course of the infection are macroscopic consequences of a multifaceted molecular …

[HTML][HTML] Repurposing of kinase inhibitors for treatment of COVID-19

E Weisberg, A Parent, PL Yang, M Sattler, Q Liu… - Pharmaceutical …, 2020 - Springer
The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …

[HTML][HTML] Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update

U Anand, S Jakhmola, O Indari, HC Jha… - Frontiers in …, 2021 - frontiersin.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic
novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID …

Fusion of enveloped viruses in endosomes

JM White, GR Whittaker - Traffic, 2016 - Wiley Online Library
Ari Helenius launched the field of enveloped virus fusion in endosomes with a seminal
paper in the Journal of Cell Biology in 1980. In the intervening years, a great deal has been …

[HTML][HTML] Mechanisms of coronavirus cell entry mediated by the viral spike protein

S Belouzard, JK Millet, BN Licitra, GR Whittaker - Viruses, 2012 - mdpi.com
Coronaviruses are enveloped positive-stranded RNA viruses that replicate in the cytoplasm.
To deliver their nucleocapsid into the host cell, they rely on the fusion of their envelope with …

The surviving sepsis campaign: research priorities for coronavirus disease 2019 in critical illness

CM Coopersmith, M Antonelli, SR Bauer… - Critical care …, 2021 - journals.lww.com
OBJECTIVES: To identify research priorities in the management, pathophysiology, and host
response of coronavirus disease 2019 in critically ill patients. DESIGN: The Surviving Sepsis …

The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as …

F Musarrat, V Chouljenko, A Dahal… - Journal of medical …, 2020 - Wiley Online Library
Severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is the causative agent of
the coronavirus disease‐2019 (COVID‐19) pandemic. Coronaviruses enter cells via fusion …

Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds …

NA Murugan, CJ Pandian… - Journal of Biomolecular …, 2021 - Taylor & Francis
The outbreak due to SARS-CoV-2 (or Covid-19) is spreading alarmingly and number of
deaths due to infection is aggressively increasing every day. Due to the rapid human to …

[HTML][HTML] Animal models for COVID-19: advances, gaps and perspectives

C Fan, Y Wu, X Rui, Y Yang, C Ling, S Liu… - … and Targeted Therapy, 2022 - nature.com
Abstract COVID-19, caused by SARS-CoV-2, is the most consequential pandemic of this
century. Since the outbreak in late 2019, animal models have been playing crucial roles in …

[PDF][PDF] Teicoplanin potently blocks the cell entry of 2019-nCoV

J Zhang, X Ma, F Yu, J Liu, F Zou, T Pan, H Zhang - biorxiv, 2020 - researchgate.net
Since December 2019, the outbreak of a new coronavirus, named 2019-nCoV, has greatly
threatened the public health in China and raised great concerns worldwide. No specific …